Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer

9Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Metabolic syndrome is reported to play a role in the genesis and development not only of angina, arteriosclerosis, diabetes, and osteoporosis but also of prostate cancer. Hypercholesterolemia is a strong risk factor in prostate cancer development. The current study was conducted to analyze whether pretreatment serum levels of cholesterol correlate with prostate cancer metastasis. Three hundred fifty-one subjects who received a histopathological diagnosis of prostate cancer were evaluated by clinical factors such as age, body mass index (BMI), disease stage, Gleason score, prostate-specific antigen (PSA), total cholesterol, Luteinizing hormone (LH), testosterone, and free testosterone. A multivariate analysis was performed on these factors, and a statistically significant difference was identified in total cholesterol level (p =.01) and PSA (p

Cite

CITATION STYLE

APA

Hirano, H., Ide, H., Lu, Y., Inoue, Y., Okada, H., & Horie, S. (2020). Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer. American Journal of Men’s Health, 14(2). https://doi.org/10.1177/1557988320918788

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free